Impax Acquires Generic Products from Actavis - Analyst Blog

By
A A A

Impax Laboratories, Inc. ( IPXL ) announced that it has acquired two generic products from Actavis plc ( ACT ) for a cash consideration.

The financial terms of the agreement were not disclosed.

As per the agreement, Impax will acquire Ursodiol tablet and Lamotrigine orally disintegrating tablet. We note that the Abbreviated New Drug Application (ANDA) for Lamotrigine has been approved but the product is not marketed yet.


The acquisition will broaden Impax's generics' portfolio which includes generic Adderall XR, fenofibrate (generic to Lofibra) and oxymorphone HCI ER.

We note that Impax has been working actively on strengthening its generic products portfolio in recent times. In Apr 2014, Impax had launched the authorized generic version of Sanofi's ( SNY ) Renvela, which will significantly boost the top line in 2014. Moreover, Impax is seeking approval for its pending ANDA for generic Renvela with the FDA.

Meanwhile, Impax is looking to get its late-stage candidate, Rytary, approved for the symptomatic treatment of Parkinson's disease. The FDA accepted Impax's re-submission of New Drug Application (NDA) for Rytary in Apr 2014.

The FDA will inspect the manufacturing facilities involved in the production of Rytary. A response from the agency should be out by Oct 9, 2014. Impax also intends to file for EU approval for Rytary in the second half of 2014.

Impax currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the healthcare sector might consider Mallinckrodt plc ( MNK ), which carries a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

IMPAX LABORATRS (IPXL): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

ACTAVIS PLC (ACT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: SNY , IPXL , MNK , ACT

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

85,117,424
  • $6.78 ▲ 11.88%
77,261,676
  • $17.53 ▲ 1.56%
61,066,548
  • $6.90 ▲ 2.99%
56,847,440
  • $112.65 ▲ 2.96%
52,788,366
  • $7.78 ▲ 1.83%
50,761,400
  • $25.14 ▲ 2.91%
47,781,237
  • $45.35 ▲ 10.18%
45,664,909
  • $7.17 ▲ 2.14%
As of 12/18/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com